Results 11 to 20 of about 1,881,376 (382)
Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus [PDF]
Cell Reports, 2017 Summary: Drug combinations are synergistic when their combined efficacy exceeds the sum of the individual actions, but they rarely include ineffective drugs that become effective only in combination. We identified several “enabling pairs” of neutralizing Katie A. Howell, Jennifer M. Brannan, Christopher Bryan, Andrew McNeal, Edgar Davidson, Hannah L. Turner, Hong Vu, Sergey Shulenin, Shihua He, Ana Kuehne, Andrew S. Herbert, Xiangguo Qiu, Benjamin J. Doranz, Frederick W. Holtsberg, Andrew B. Ward, John M. Dye, M. Javad Aman +16 moredoaj +3 more sourcesEarly Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
New England Journal of Medicine, 2021 BACKGROUND
Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Anil K Gupta, Y. Gonzalez-Rojas, Erick Juarez, M. Crespo Casal, J. Moya, D. Falci, E. Sarkis, Joel Solis, Hanzhe Zheng, Nicola E. Scott, A. Cathcart, C. Hebner, J. Sager, E. Mogalian, C. Tipple, A. Peppercorn, Elizabeth L. Alexander, P. Pang, A. Free, C. Brinson, M. Aldinger, A. Shapiro +21 moresemanticscholar +1 more sourceA gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition [PDF]
, 2013 The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broadly neutralizing antibodies 2F5 and 4E10. To date, no immunization regimen in animals or humans has produced HIV-1 neutralizing MPER-specific antibodies ...Aasa-Chapman, Marlén M. I., Battella, Simone, Bonvin, Alexandre M. J. J., Davis, David, El Khattabi, Mohamed, Favier, Adrien, Forsman Quigley, Anna, Hinz, Andreas, Hock, Miriam, Hulsik, David Lutje, Langedijk, Johannes P. M., Liu, Ying-ying, Macheboeuf, Pauline, McCoy, Laura E., Poignard, Pascal, Ramos, Alejandra, Rutten, Lucy, Sabin, Charles, Seaman, Michael S., Simorre, Jean-Pierre, Strokappe, Nika M., Verrips, C. Theo, Weiss, Robin A., Weissenhorn, Winfried +23 morecore +18 more sourcesNeutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
Nature Communications, 2021 Understanding how antibody responses to SARS-CoV-2 evolve during infection may provide important insight into therapeutic approaches and vaccination for COVID-19.S. Dispinseri, M. Secchi, M. Pirillo, M. Tolazzi, M. Borghi, C. Brigatti, M. D. De Angelis, M. Baratella, E. Bazzigaluppi, G. Venturi, F. Sironi, A. Canitano, I. Marzinotto, C. Tresoldi, F. Ciceri, L. Piemonti, D. Negri, A. Cara, V. Lampasona, G. Scarlatti +19 moresemanticscholar +1 more sourceNeutralizing antibody titres in SARS-CoV-2 infections
Nature Communications, 2021 The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed.E. Lau, O. Tsang, D. Hui, M. Kwan, Wai-Hung Chan, S. Chiu, R. Ko, K. Chan, Samuel M. S. Cheng, Ranawaka A.P.M Perera, B. Cowling, L. Poon, M. Peiris +12 moresemanticscholar +1 more sourceEngineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways
iScience, 2022 Summary: The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein have been shown to disrupt antibody binding and ...Fangzhu Zhao, Celina Keating, Gabriel Ozorowski, Namir Shaabani, Irene M. Francino-Urdaniz, Shawn Barman, Oliver Limbo, Alison Burns, Panpan Zhou, Michael J. Ricciardi, Jordan Woehl, Quoc Tran, Hannah L. Turner, Linghang Peng, Deli Huang, David Nemazee, Raiees Andrabi, Devin Sok, John R. Teijaro, Timothy A. Whitehead, Andrew B. Ward, Dennis R. Burton, Joseph G. Jardine +22 moredoaj +1 more sourceThe neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Science Translational Medicine, 2021 LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection. A monoclonal for SARS-CoV-2 Among the most promising therapeutic options for individuals with coronavirus ...Bryan E. Jones, P. Brown-Augsburger, Kizzmekia S. Corbett, Kathryn Westendorf, J. Davies, T. Cujec, C. Wiethoff, J. Blackbourne, B. Heinz, Denisa Foster, R. Higgs, D. Balasubramaniam, Lingshu Wang, Yi Zhang, E. Yang, Roza Bidshahri, Lucas Kraft, Yuri Hwang, Stefanie Žentelis, Kevin R. Jepson, R. Goya, Maia A. Smith, D. W. Collins, Samuel J. Hinshaw, Sean A. Tycho, Davide Pellacani, Ping Xiang, Krithika Muthuraman, S. Sobhanifar, Marissa H. Piper, Franz J. Triana, J. Hendle, A. Pustilnik, A. Adams, Shawn J. Berens, R. Baric, David R. Martinez, R. Cross, T. Geisbert, V. Borisevich, O. Abiona, H. Belli, M. de Vries, Adil Mohamed, Meike Dittmann, M. Samanovic, M. Mulligan, J. Goldsmith, C. Hsieh, N. Johnson, D. Wrapp, J. McLellan, B. Barnhart, B. Graham, J. Mascola, C. Hansen, E. Falconer +56 moresemanticscholar +1 more sourceREGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
New England Journal of Medicine, 2020 Background Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind, phase 1–3 trial involving nonhospitalized patients with Covid-19, we ...D. Weinreich, S. Sivapalasingam, Thomas D. Norton, Shazia Ali, Haitao Gao, R. Bhore, B. Musser, Y. Soo, D. Rofail, Joseph Im, C. Perry, C. Pan, R. Hosain, A. Mahmood, John D. Davis, K. Turner, A. Hooper, J. Hamilton, A. Baum, C. Kyratsous, Yunji Kim, A. Cook, W. Kampman, A. Kohli, Yessica Sachdeva, X. Graber, B. Kowal, T. Dicioccio, N. Stahl, L. Lipsich, N. Braunstein, G. Herman, G. Yancopoulos +32 moresemanticscholar +1 more sourceNeutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
Science Translational Medicine, 2022 The waning efficacy of SARS-CoV-2 vaccines, combined with the continued emergence of variants resistant to vaccine-induced immunity, has reignited debate over the need for booster vaccine doses.John P. Evans, C. Zeng, Claire Carlin, G. Lozanski, L. Saif, Eugene M. Oltz, R. Gumina, Shan-Lu Liu +7 moresemanticscholar +1 more sourceVaccination induces HIV broadly neutralizing antibody precursors in humans
Science, 2022 Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled David J. Leggat, Kristen W. Cohen, Jordan R. Willis, W. Fulp, Allan C. deCamp, O. Kalyuzhniy, C. Cottrell, Sergey Menis, Greg Finak, Lamar Ballweber-Fleming, Abhinaya Srikanth, Jason R. Plyler, Torben Schiffner, Alessia Liguori, Farhad Rahaman, Angela Lombardo, V. Philiponis, Rachael E. Whaley, A. Seese, Joshua Brand, Alexis M Ruppel, W. Hoyland, N. Yates, L. D. Williams, Kelli M. Greene, Hongmei Gao, Celia Mahoney, M. Corcoran, A. Cagigi, Alison Taylor, David M. Brown, D. Ambrozak, Troy Sincomb, Xiaozhen Hu, Ryan D. Tingle, Erik Georgeson, Saman Eskandarzadeh, Nushin B Alavi, Danny Lu, T. Mullen, Michael Kubitz, Bettina Groschel, J. Maenza, O. Kolokythas, N. Khati, J. Bethony, S. Crotty, M. Roederer, G. K. Karlsson Hedestam, G. Tomaras, D. Montefiori, D. Diemert, R. Koup, D. Laufer, M. McElrath, A. McDermott, W. Schief +56 moresemanticscholar +1 more source